Monday 13 October 2014

Theranos: The World's Best Healthcare Company

Introduction to Theranos

TheranosEver since their debut article in Fortune this June, in which Theranos unveiled its stature as a $9B-valued company poised to completely disrupt the $78B per year laboratory diagnostics industry, Theranos has been lavishly featured in the media as a herald of the new healthcare: Affordable, personal, transparent, and accessible. Theranos is built around a proprietary new high-complexity diagnostics lab that allows for a large range of tests (they currently list 229 on their website, but the Fortune article tells us they'll soon offer over 1,000) to be run on blood and other bodily fluids using much smaller sample sizes (70 separate tests can be run on a single sample of a few drops of blood: 1/1000th the amount of blood needed for traditional tests) for a very low cost (Theranos's prices are always 50-90% less than the Medicare reimbursement codes. For example, a standard metabolic panel would cost ~$46 at a standard lab, Medicare would reimburse $14.74, and Theranos charges only $7.27. The average price across their 229 tests is $12.92), and at exceptional speed (whereas traditional testing services would take days to return results, Theranos's labs take mere hours). The Theranos labs also require less footprint, allowing them to be housed in small corners of retail clinics, hospitals, and other existing healthcare outlets. They have signed a non-exclusive agreement with Walgreens (the pharmacy chain currently boasts over 8,200 brick-and-mortar pharmacy locations in the U.S.) to build Theranos Wellness Centers in each location as quickly as possible. They are already operating out of 39 Walgreens stores in Arizona, and 1 in Palo Alto, California. They have also inked agreements with several hospital systems, such as Intermountain Healthcare and Dignity.

Whence Theranos on 

Before explaining why Theranos is the best healthcare company in the world, it's worth explaining why is featuring Theranos in the first place; after all, the company maintains over 500 employees in a 111,000 square-ft. facility at Stanford University, and even manufacturers their labs at a 262,000 square-ft. factory in Newark, California. Their board is also unusually stacked with American civil heroes such as Henry Kissinger, William Perry, and James Mattis. Theranos is as American a company as they come, but there are good reasons to feature Theranos as the first innovation profile on a site dedicated to researching technologies originating from emerging markets. The first is that Holmes's (Elizabeth Holmes is the Founder and CEO of Theranos, a very focused and brilliant person who dropped out of Stanford's Chemistry program as a Sophomore to start this company) idea for Theranos seems to have originated from a 2003 summer internship (Holmes founded Theranos in the fall of 2003) at the Genome Institute of Singapore during their work with Roche Diagnostics to make highly affordable, accessible, and fast SARS testing kits available to the Asia-Pacific region using their nobel-prize-winning PCR technology. 

The second reason is that Theranos is such a complete example of a healthcare innovation, a standard by which all of the individual foreign technologies will feature must aspire to within the transplanted context of the U.S. healthcare market. The fact is that any technological innovation in isolation is naked, and really not worth much until it is clothed in the appropriate vestments of an integrated market application and comprehensive business model that delights each of its stakeholders. Like Edison, true disruptors must invent more than just a lightbulb: They must also design and execute a workable electrical grid into which the lightbulb can integrate.

Why Theranos is the World's Best Healthcare Company

Reason 1: Theranos's Market Position in Diagnostics
Successfully designing their 'electrical grid' is the second-most important reason why Theranos is the world's best healthcare company. The first is that they may credibly become the 'gatekeeper of healthcare' by owning the market for laboratory diagnostics, the data of which already form the basis of 70-80% of clinical decisions. This number will only increase as the speed, reliability, accuracy, breadth, price, and accessibility of diagnostic information increases--all of which Theranos is accomplishing. Additionally, diagnostics is the nexus of healthcare most amenable to expanding the scope of practice of lower-cost providers for well-understood medical conditions. As another of our posts explores, this is one of the surest ways to decrease healthcare costs in the U.S. 

Reason 2: Theranos's Business Model
Every component of a good business model flows from, and seeks to balance and reconcile, the foundational stakeholder value propositions (VPs) upon which the success of the business depends. These VPs are responses to stakeholder jobs-to-be-done (JTBD). Below are some examples of the primary stakeholders, their JTBD related to lab diagnostics, and the resultant VPs that Theranos has so expertly constructed its offerings around:

  • Patients
  • Providers
    • JTBD
      1. Fast, accurate test results
      2. Easily place orders and follow-up orders
      3. Easily consumable reporting
      4. Not take up much space (hospitals)
    • VPs
      1. Results w/in hours instead of days; high illustrative accuracy 
      2. Send samples using existing infrastructure OR send patient to Wellness Center
      3. Alerts and easily consumable graphs via software
      4. Theranos labs require 10x-100x less space than traditional labs 
  • Payers
  • Regulators

Challenges In Emerging Markets for Theranos

Theranos is a careful company. They were in stealth mode for 10 years making sure to nail each piece of their business model before starting to scale, and they are doing that very deliberately so far with Walgreens. Holmes has indicated that Theranos is systematically evaluating a global expansion strategy, which will probably not happen tomorrow. If it does happen, each new market will of course require an entirely new business model, or configuration among a separate set of stakeholders.

Research on the laboratory diagnostic market in India indicates that Theranos would today be a welcome innovation within this market since the vast majority of diagnostic labs in India are importing equipment from the same OEMs that supply the traditional diagnostic labs in the U.S., e.g. Siemens, Olympus, and Beckman Coulter. Because of this, even the Indian test prices are still higher than those of Theranos as the table below comparing the cost of a few Theranos and SRL Diagnostics tests shows:

But price is just one metric, and others may be just as important in emerging markets. For instance, Dr. Natarajan Sriram wrote a critical piece about existing IVDs in emerging markets, and while price was at the top of the list of criticisms, there are many additional reasons that make significant market penetration difficult for laboratory-based diagnostics. Dr. Sriram outlines important performance dimensions required for IVD products to succeed in emerging markets. While Theranos performs well on several cost and reliability metrics, there are a few that Theranos will find difficult to excel on in its current form:

  1. Simple and minimum end-to-end procedure
  2. Test results require no additional equipment or accessories from site of test
  3. Small pack size of IVD
  4. Minimal training required w/ no professional staff
Rapid Diagnostic Test
Typical Rapid Diagnostic Device
Dr. Sriram's own company, the Tulip Group, oversees the R&D and production of Rapid Diagnostic Tests (RDTs), which are typically single-use applications meant to test for the presence of an infectious disease, exactly like that of Roche's PCR system for SARS in 2003. While incremental cost advantages to RDTs have been shown at high levels of a particular disease prevalence, their true advantage in emerging markets is that they satisfy the above criteria for success that Dr. Sriram outlines. 

The penetration of Theranos into emerging markets in its current form might rely on how widely held and acute the JTBD of 'help me watch a movie of my micro-biological health indicators over time' is in these markets since the OEMs already supplying the equipment will likely soon provide lower-cost lab diagnostics to achieve cost parity with Theranos. 

I wonder, might Theranos carry their genius of miniaturization a bit further to create portable laboratories, patches, or more versatile RDTs in order to succeed in emerging markets as they will succeed in the U.S.? 

RDT photo credit:


  1. Every Business looking KOL Management for their business growth, if you want ideas and suggestions to make your business more profit just get the help from Market Research Companies in India.
    Market Research Companies in India | Top Market Research Companies in India

  2. Well said! Key Opinion leaders play a vital role in the development of pharmaceutical organization. Hence it is recommended that the organization take necessary steps for building KOL relationship and managing them effectively.
    KOL management | Key Opinion Leader Management

  3. i think if you had diagrams from it would be easir for people understand what you were saying in your post!but anyway thank you for your time and hard work on this one!

  4. Thanks a lot very much for the high quality and results-oriented help.
    I won’t think twice to endorse your blog post to anybody who wants
    and needs support about this area.
    syringe infusion pumps

    infusion pumps manufacturers

    patient monitor manufacturers

  5. The postings on your site are always excellent. i really loved the content in it Thanks for the sharing please keep updating.My friend recommended this blog and he was totally right keep up the fantastic work!

    Dengue RT PCR Kit

  6. This is a very nice informative post. I really enjoyed reading your post. Thank's for sharing your post.
    mats institute in bangladesh

  7. 3. We pour the boiling water on the ants tunnels and this is easy in case it is difficult to demolish the tunnels.

    We place utensils filled with water mixed with kerosene in food cupboards and cabinets.شركة مكافحة النمل الابيض بالدمام
    شركة مكافحة حشرات بالدمام
    شركة رش مبيدات بالدمام
    افضل شركة مكافحة حشرات

  8. The healthcare sector includes such businesses. Provide medical services, make medical devices or medicines.

  9. Spider Car Rental is one stop for Luxury Cars & Limousine Services in Dubai where a customer can select the car, pay online and get it delivered within one hour anywhere in Dubai. Ferrari rent in Dubai

  10. Spider Car Rental is one stop for Luxury Cars & Limousine Services in Dubai where a customer can select the car, pay online and get it delivered within one hour anywhere in Dubai. Car with driver in Dubai

  11. Theranos is the best health company. Your Doctors are well trained. Patients are satisfied from you. With that, I will publicity to your work through USA SEO Company. You can get our service for local and commercial business.

  12. high levels of a particular disease prevalence. Essay Champ their true advantage in emerging markets is that they satisfy the above criteria for success.

  13. All of the beneficial casinos listed here are|listed beneath are} legitimate websites 카지노 that hold gamers safe. They respect playing guidelines and age restrictions, providing a superb real money gaming experience in a safe surroundings devoted to gamers' welfare and security on-line. Yes, we won’t advocate any website on the internet who has had points with players’ data going bye-bye.